Lannett has added another respiratory generic to its development partnership with China’s Respirent, in the form of a rival to Boehringer Ingelheim’s tiotropium-based Spiriva Handihaler.
Lannett will market Respirent’s generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) in the US, under the terms of an exclusive distribution agreement that has been announced by the US firm with the Chinese respiratory developer.
While financial terms were not disclosed, Lannett revealed that “the 10-year term of the agreement commences upon distribution of the...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
